新诺威12月22日公告，公司董事会当天收到公司董事 CAI LEI（蔡磊）的书面辞职报告，蔡磊因工作变 动原因申请辞任公司董事职务，辞任后不再担任公司任何职务。蔡磊的辞职报告自送达董事会时生效。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事离任情况 证券代码：300765 证券简称：新诺威 公告编号：2025-100 石药创新制药股份有限公司 关于董事离任的公告 CAI LEI（蔡磊）先生的辞职报告。 特此公告。 石药创新制药股份有限公司 董事会 2025 年 12 月 22 日 1 石药创新制药股份有限公司（以下简称"公司"）董事会于本日（2025 年 12 月 22 日）收到公司董事 CAI LEI（蔡磊）先生的书面辞职报告，具体情况如下： 因工作变动原因，CAI LEI（蔡磊）先生申请辞任公司董事职务,辞任后不再 担任公司任何职务。CAI LEI（蔡磊）先生的原定任期届满之日为 2026 年 4 月 6 日，其辞任未导致公司董事会人数低于法定最低人数，其辞职报告自送达董事会 时生效。截至本公告披露之日，CAI LEI（蔡磊）先生未直接持有公司股份。辞 去相关职务后，CAI LEI（蔡磊）先生将继续严格遵守国家相关法律、法规及《上 市公司股东、董监高减持股份的若干规定》《深圳证券交易所上市公司股东及董 事、监事、高级管理人员减持股份实施 ...

石药创新制药股份有限公司（以下简称"公司"或"上市公司"）第六届董事会 第二十九次会议（以下简称"本次会议"）于 2025 年 12 月 22 日在公司会议室以 现场加通讯表决相结合的方式召开，会议通知于 2025 年 12 月 19 日以专人送出、 电话通知等方式送达全体董事。 会议由公司董事长姚兵先生主持，公司高级管理人员列席了本次会议。本次 会议应出席董事人数 9 人，实际出席董事人数 9 人。出席董事资格、人数以及召 集、召开程序等均符合《中华人民共和国公司法》等法律法规和《石药创新制药 股份有限公司章程》的规定，本次会议合法有效。 证券代码：300765 证券简称：新诺威 公告编号：2025-098 石药创新制药股份有限公司 第六届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：同意 6 票，反对 0 票，弃权 0 票，回避 3 票。 三、备查文件 1、石药创新制药股份有限公司第六届董事会第二十九次会议决议； 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议并通过了如下议案： 1 ...

2、本次交易构成关联交易，不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。 证券代码：300765 证券简称：新诺威 公告编号：2025-099 石药创新制药股份有限公司 关于与关联方共同投资设立合资公司暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、石药创新制药股份有限公司（以下简称"公司"或"石药创新"）拟与石药 集团中奇制药技术（石家庄）有限公司（以下简称"中奇制药"）共同出资 45,000 万元人民币设立合资公司，其中公司拟以自有资金出资 15,750 万元，占合资公 司注册资本的 35%；中奇制药拟以自有资金出资 29,250 万元，占合资公司注册 资本的 65%（以下简称"本次交易"）。 （二）关联关系情况 3、本次关联交易事项已经公司第六届董事会第十五次独立董事专门会议、 第六届董事会第二十九次会议审议通过，在董事会审议时关联董事已回避表决。 本次关联交易事项在公司董事会审批权限范围内，无需提交公司股东会审议。 4、截至本公告披露日，合资公司尚未注册成立，名称及相关工商信息将以 最终登记注册信息为准， ...

Core Viewpoint - The company, formerly known as XinNuoWei, is rebranding as Shiyao Innovation and aims to enter the international capital market after acquiring a majority stake in Jushi Biotech, expanding its business into innovative biopharmaceuticals [2][4]. Group 1: Company Overview - Shiyao Innovation was established in April 2006 with a registered capital of 8.3 million yuan and was spun off from Shiyao Group in March 2019 [5]. - The company has undergone multiple acquisitions, including the purchase of 100% of Shiyao Shengxue for 800 million yuan, resulting in a premium acquisition rate of 121% [5]. - As of July 2023, Shiyao Innovation's total assets reached approximately 205.73 billion yuan, with total liabilities of about 136.88 billion yuan [7]. Group 2: Business Expansion - The acquisition of Jushi Biotech aims to propel Shiyao Innovation into the innovative biopharmaceutical sector, with biopharmaceutical revenue increasing eightfold in the first seven months of 2025 [4][14]. - The company has diversified its product offerings, including biopharmaceuticals, functional raw materials, and health foods, with a significant focus on caffeine production [13]. Group 3: Financial Performance - Revenue from functional raw materials and health foods has been declining, contributing to an overall revenue drop from 28.38 billion yuan in 2022 to 19.81 billion yuan in 2024 [13]. - In contrast, biopharmaceutical revenue has surged, contributing 1.18 billion yuan in the first seven months of 2025, marking a significant recovery [14]. - The company reported a net loss of 3.04 billion yuan in 2024, with a further loss of 2.26 billion yuan in the first seven months of 2025 [23]. Group 4: Shareholder Dynamics - Shiyao Group holds a 75.3% stake in Shiyao Innovation, making it the controlling shareholder [8]. - The company has engaged in significant related-party transactions with Shiyao Group, which has been both a major customer and supplier [18][19]. Group 5: Management Changes - The company has seen changes in its executive leadership, with Yao Bing becoming the new chairman and general manager in 2024 [10][11]. - The CFO, Dai Long, is a relatively young executive, having joined the company in 2016 and taking on the CFO role in 2023 [12].

广发医疗保健股票A（004851）基金经理为吴兴武。 截至发稿，吴兴武累计任职时间10年317天，现任基金资产总规模106.41亿元，任职期间最佳基金回报 89.3%， 任职期间最差基金回报-42.12%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 12月22日，新诺威涨5.1%，截至发稿，报36.46元/股，成交3.12亿元，换手率0.63%，总市值512.11亿 元。新诺威股价已经连续3天上涨，区间累计涨幅20.87%。 资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号,香港湾仔港湾道18号中 环广场32楼3206室，成立日期2006年4月5日，上市日期2019年3月22日，公司主营业务涉及功能食品的 研发、生产与销售。主营业务收入构成为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。 从基金十大重仓股角度 数据显示，广发基金旗下1只基金重仓新诺威。广发医疗保健股票A（004851）三季度增持6400股 ...

Market Performance - The chemical pharmaceutical sector increased by 1.95% on December 19, with XinNuoWei leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Top Gainers in Chemical Pharmaceutical Sector - XinNuoWei (300765) closed at 34.69, up 11.44%, with a trading volume of 311,700 shares and a transaction value of 1.069 billion [1] - KangYi Pharmaceutical (300086) closed at 11.02, up 11.43%, with a trading volume of 965,500 shares and a transaction value of 1.018 billion [1] - MuNanHai Pharmaceutical (000566) closed at 7.24, up 10.03%, with a trading volume of 1,325,900 shares and a transaction value of 914 million [1] Market Capital Flow - The chemical pharmaceutical sector saw a net inflow of 68.1822 million from institutional investors, while retail investors contributed a net inflow of 31.3 million [2] - The sector experienced a net outflow of 381 million from speculative funds [2] Individual Stock Capital Flow - ST Renfu (600079) had a net inflow of 92.7508 million from institutional investors, while it faced a net outflow of 26.4283 million from speculative funds [3] - GuangShengTang (300436) recorded a net inflow of 49.2520 million from institutional investors, with a net outflow of 17.4322 million from speculative funds [3] - KangZhi Pharmaceutical (300086) had a net inflow of 28.1873 million from institutional investors, while it faced a net outflow of 3.1280 million from retail investors [3]

据天眼查APP显示，石药创新制药股份有限公司成立于2006年04月05日，注册资本140459.2944万人民 币。（数据宝） 数据宝统计，截至14:42，新诺威成交额10.05亿元，创2025年4月30日以来新高。最新股价上涨 11.60%，换手率2.09%。上一交易日该股全天成交额为5.87亿元。 （文章来源：证券时报网） ...

Market Overview - The A-share market experienced an overall upward trend on December 19, with major indices showing varying degrees of increase. The Shanghai Composite Index closed at 3899.31 points, up 0.59%, briefly surpassing 3900 points during the session [1] - Other major indices also saw gains, with the Shenzhen Component Index rising by 0.93%, the ChiNext Index increasing by 0.99%, and the STAR 50 Index up by 0.69% [1] Sector Performance - The retail sector saw significant gains, with the sector's index rising nearly 4% at one point during the trading session. This led to a surge in individual stock performances within the sector [1] - Notable stocks that hit the daily limit include Debi Group (300947), Central Plaza (600280), Shanghai Jiubai (600838), Dalian Friendship (000679), and Dongbai Group (600693) [1] - Other retail stocks such as Baida Group (600865) and Yonghui Supermarket (601933) also performed well, increasing by 9.25% and 8.20% respectively [1] Consumer Concepts - The duty-free, dairy, and new retail sectors also saw substantial increases, with several stocks rising over 10%. Stocks such as Chuangyuan Co. (300703), Huanlejia (300997), and Xinnuo Wei (300765) were among those that performed exceptionally well [1] - Additional stocks that reached their daily limit include Xiwang Food (000639), Hongmian Co. (000523), Zhuangyuan Pasture (002910), Tianchuang Fashion (603608), Xinhua Du (002264), and Jiumuwang (601566) [1] - Other notable performers included Haikong Group (603069), China Duty Free Group (601888), and Knight Dairy, which all saw increases exceeding 7% [1]

从基金十大重仓股角度 数据显示，诺安基金旗下1只基金重仓新诺威。诺安精选价值混合A（001900）三季度增持47.06万股， 持有股数95.43万股，占基金净值比例为4.9%，位居第八大重仓股。根据测算，今日浮盈赚取约160.32 万元。 12月19日，新诺威涨5.4%，截至发稿，报32.81元/股，成交1.19亿元，换手率0.26%，总市值460.85亿 元。 资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号,香港湾仔港湾道18号中 环广场32楼3206室，成立日期2006年4月5日，上市日期2019年3月22日，公司主营业务涉及功能食品的 研发、生产与销售。主营业务收入构成为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。 诺安精选价值混合A（001900）成立日期2019年2月28日，最新规模2.82亿。今年以来收益63.35%，同 类排名426/8098；近一年收益57.49%，同类排名527/8067；成立以来收益59.87%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、 ...